Page last updated: 2024-10-15

5,6,7,8-tetrahydrofolic acid

Description

tetrahydrofolic acid : A group of heterocyclic compounds based on the 5,6,7,8-tetrahydropteroic acid skeleton conjugated with one or more L-glutamic acid units. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

tetrahydrofolate : A folate obtained by deprotonation of any tetrahydrofolic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

5,6,7,8-tetrahydrofolic acid: RN given refers to (DL)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135444742
CHEMBL ID91866
CHEMBL ID2021342
CHEBI ID20506
CHEBI ID68512
SCHEMBL ID82453
MeSH IDM0096115
PubMed CID135415876
CHEMBL ID2074655
CHEBI ID166569
SCHEMBL ID8031
MeSH IDM0096115

Synonyms (63)

Synonym
einecs 205-181-1
n-(4-(((2-amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-l-glutamic acid
tetrahydropteroylglutamic acid
glutamic acid, n-(p-(((2-amino-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-, l-
CHEBI:20506 ,
n-[4-{[(2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}benzoyl]-l-glutamic acid
l-glutamic acid, n-(4-(((2-amino-1,4,5,6,7,8-hexahydro-4-oxopteridinyl)methyl)amino)benzoyl)-
l-glutamic acid, n-[4-[[(2-amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-
135-16-0
tetrahydrofolic acid
tetrahydrofolate
tetrahydrofolic acid, >=65% (when packaged), powder
DB00116
2-{4-[(2-amino-4-oxo-1,4,5,6,7,8-hexahydro-pteridin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid
bdbm50022833
chembl91866
(s)-2-{4-[(2-amino-4-oxo-1,4,5,6,7,8-hexahydro-pteridin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid
43zwb253h4 ,
unii-43zwb253h4
CHEMBL2021342
CHEBI:68512
tetrahydrofolyl-(l-glu)n
gtpl4675
(2s)-2-[(4-{[(2-amino-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid
SCHEMBL82453
(2s)-2-(4-(((2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzamido)pentanedioic acid
AKOS022174895
l-glutamic acid, n-(4-(((2-amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-
(-)-l-5,6,7,8-tetrahydrofolic acid
tetrahydrofolic acid [dsc]
l-glutamic acid, n-[4-[[(2-amino-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-
AC-31120
c19h23n7o6
mfcd00135583
J-006656
DS-7498
DTXSID70897520
(2s)-5,6,7,8-tetrahydrofolic acid
Q53668656
(2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-3h-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
5,6,7,8-tetrahydropteroyl-l-glutamic acid
(2s)-2-(4-((2-amino-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methylamino)benzamido)pentanedioic acid
CS-0003422
HY-14520
A910085
tetrahydrofolicacid
5,6,7,8-tetrahydropteroyl-l-glutamic acid, thf
AKOS040744825
6r-tetrahydrofolic acid
CHEBI:166569
(2s)-2-[[4-[[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-3h-pteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
5,6,7,8-tetrahydrofolic acid
bdbm50391006
CHEMBL2074655 ,
n-[4-({[(6r)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-l-glutamic acid
SCHEMBL8031
(6r)-tetrahydrofolic acid
MSTNYGQPCMXVAQ-NEPJUHHUSA-N
(2s)-2-[(4-{[(6r)(2-amino-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid
[6r]-tetrahydrofolic acid
(2s)-2-[[4-[[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
(2s,6r)-5,6,7,8-tetrahydrofolic acid
Q27452575

Toxicity

ExcerptReference
" However, the mechanism by which formaldehyde mediates these toxic effects is still unknown."( Genotoxicity of tetrahydrofolic acid to hematopoietic stem and progenitor cells.
Bejarano-García, JA; Caballero-Velázquez, T; Castro, MJ; García-Calderón, CB; Moreno-Gordillo, P; Pérez-Simón, JA; Piruat, JI; Rosado, IV; Tinoco-Gago, I, 2018
)

Pharmacokinetics

ExcerptReference
" Plasma was collected for pharmacokinetic (PK) analysis before, during, and after surgery."( A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study.
Derwinger, K; Kodeda, K; Odin, E; Taflin, H; Wettergren, Y, 2015
)

Bioavailability

ExcerptReference
" Furthermore, FA improved redox status of Ang II treated cells by increasing H(4)B and NO() bioavailability while decreasing superoxide (O(2)(-)) production."( Mechanistic insights into folic acid-dependent vascular protection: dihydrofolate reductase (DHFR)-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: a novel HPLC-based fluorescent assay for DHFR activity.
Cai, H; Chalupsky, K; Gao, L; Stefani, E, 2009
)
" In this study, we evaluated short-term folate bioavailability in rats infused with this folate-biofortified fruit."( Natural folates from biofortified tomato and synthetic 5-methyl-tetrahydrofolate display equivalent bioavailability in a murine model.
Castorena-Torres, F; de la Garza, RI; García-Rivas, G; Hernández-Méndez, RV; Ramos-Parra, PA; Vargas-García, A, 2014
)

Dosage Studied

ExcerptReference
" A common dosage of leucovorin in adjuvant and palliative settings is 60 mg/m(2)."( Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages.
Derwinger, K; Odin, E; Taflin, H; Wettergren, Y, 2014
)
" Further studies are needed to establish whether higher dosage yields a better treatment response."( Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages.
Derwinger, K; Odin, E; Taflin, H; Wettergren, Y, 2014
)
"Thirty-two patients scheduled for colon resection were randomized to receive Modufolin® or Isovorin® at dosage of 60 or 200 mg/m²."( A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study.
Derwinger, K; Kodeda, K; Odin, E; Taflin, H; Wettergren, Y, 2015
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
tetrahydrofolic acidA group of heterocyclic compounds based on the 5,6,7,8-tetrahydropteroic acid skeleton conjugated with one or more L-glutamic acid units.
tetrahydrofolic acidA group of heterocyclic compounds based on the 5,6,7,8-tetrahydropteroic acid skeleton conjugated with one or more L-glutamic acid units.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
Folate-alcohol and cancer pathway012
Folate-alcohol and cancer pathway hypotheses012
Disorders of folate metabolism and transport1827
Vitamin B12 disorders1313

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Canalicular multispecific organic anion transporter 1Rattus norvegicus (Norway rat)Ki358.00000.84004.968210.0000AID679311
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseEscherichia coli K-12Kd0.22000.00001.24596.6000AID57251; AID57256; AID57262
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Folylpolyglutamate synthase, mitochondrialMus musculus (house mouse)Km3,550,004.00008.00008.00008.0000AID71200; AID71382
Folylpolyglutamate synthase, mitochondrialHomo sapiens (human)Km4.20000.40004.53447.3000AID71218
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
10-formyltetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to xenobiotic stimulusDihydrofolate reductaseEscherichia coli K-12
folic acid biosynthetic processDihydrofolate reductaseEscherichia coli K-12
one-carbon metabolic processDihydrofolate reductaseEscherichia coli K-12
response to methotrexateDihydrofolate reductaseEscherichia coli K-12
tetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to antibioticDihydrofolate reductaseEscherichia coli K-12
dihydrofolate metabolic processDihydrofolate reductaseEscherichia coli K-12
folic acid metabolic processDihydrofolate reductaseEscherichia coli K-12
liver developmentFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
nucleobase-containing compound metabolic processFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
glutamate metabolic processFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
one-carbon metabolic processFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
folic acid-containing compound metabolic processFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
animal organ regenerationFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
folic acid metabolic processFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
tetrahydrofolylpolyglutamate biosynthetic processFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
dihydrofolate reductase activityDihydrofolate reductaseEscherichia coli K-12
protein bindingDihydrofolate reductaseEscherichia coli K-12
folic acid bindingDihydrofolate reductaseEscherichia coli K-12
oxidoreductase activityDihydrofolate reductaseEscherichia coli K-12
NADP bindingDihydrofolate reductaseEscherichia coli K-12
methotrexate bindingDihydrofolate reductaseEscherichia coli K-12
dihydrofolic acid bindingDihydrofolate reductaseEscherichia coli K-12
NADP+ bindingDihydrofolate reductaseEscherichia coli K-12
NADPH bindingDihydrofolate reductaseEscherichia coli K-12
tetrahydrofolylpolyglutamate synthase activityFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
ATP bindingFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
metal ion bindingFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
cytosolDihydrofolate reductaseEscherichia coli K-12
cytosolDihydrofolate reductaseEscherichia coli K-12
mitochondrial inner membraneFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
mitochondrial matrixFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
cytosolFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
cytoplasmFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
mitochondrionFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
cytosolFolylpolyglutamate synthase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID57085Dissociation rate constant of compound for mutant T46A Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID71205Activity (relative Vmax) was evaluated in vitro by purified mouse liver folate polyglutamate synthetase (FPGS). 1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin.
AID57427Rate of hydride transfer (E-N) of compound for mutant T46A Escherichia coli dihydrofolate reductase; ND=no data1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID57431Rate of hydride transfer (E-NH) of compound for mutant T46A Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID71203Activity (relative Km ) was evaluated in vitro by purified mouse liver folate polyglutamate synthetase (FPGS). 1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin.
AID57433Rate of hydride transfer (E-NH) of compound for mutant T46S Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID57432Rate of hydride transfer (E-NH) of compound for mutant T46N Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID230430It is the ratio of apparent kinetic constant to that of relative maximum velocity1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Folate analogues. 35. Synthesis and biological evaluation of 1-deaza, 3-deaza, and bridge-elongated analogues of N10-propargyl-5,8-dideazafolic acid.
AID57430Rate of hydride transfer (E-N) of compound for wild type Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID57251Thermodynamic Dissociation Constant for compound-Phe31-dihydrofolate reductase (DHFR) complex at pH 71988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase.
AID57088Dissociation rate constant of compound for wild type Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID57087Dissociation rate constant of compound for mutant T46S Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID57429Rate of hydride transfer (E-N) of compound for mutant T46S Escherichia coli dihydrofolate reductase; ND=no data1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID57262Thermodynamic Dissociation Constant for compound-Val31-dihydrofolate reductase (DHFR) complex at pH 71988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase.
AID71229Relative maximum velocity of substrate activity for Hog liver Folyl-polyglutamate synthase (relative to control of 50 uM aminopterin)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Folate analogues. 35. Synthesis and biological evaluation of 1-deaza, 3-deaza, and bridge-elongated analogues of N10-propargyl-5,8-dideazafolic acid.
AID57434Rate of hydride transfer (E-NH) of compound for wild type Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID71200Activity (apparent Km ) was evaluated in vitro by purified mouse liver folate polyglutamate synthetase (FPGS). 1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin.
AID57428Rate of hydride transfer (E-N) of compound for mutant T46N Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID71218Apparent kinetic constant of substrate activity for Hog liver Folyl-polyglutamate synthase1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Folate analogues. 35. Synthesis and biological evaluation of 1-deaza, 3-deaza, and bridge-elongated analogues of N10-propargyl-5,8-dideazafolic acid.
AID71382The apparent Km of compound as a substrate for partially purified mouse liver Folyl-polyglutamate synthase1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
(6R,6S)-5,8,10-trideaza-5,6,7,8-tetrahydrofolate and 6(R,6S)-5,8,10-trideaza-5,6,7,8-tetrahydropteroyl-L-ornithine as potential antifolates and antitumor agents.
AID57256Thermodynamic Dissociation Constant for compound-Tyr31-dihydrofolate reductase (DHFR) complex at pH 71988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase.
AID57086Dissociation rate constant of compound for mutant T46N Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID679311TP_TRANSPORTER: inhibition of DNP-SG uptake in bile canalicular membrane vesicles from SD rat1998The American journal of physiology, 10, Volume: 275, Issue:4
Reduced folate derivatives are endogenous substrates for cMOAT in rats.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (351)

TimeframeStudies, This Drug (%)All Drugs %
pre-199076 (21.65)18.7374
1990's81 (23.08)18.2507
2000's92 (26.21)29.6817
2010's88 (25.07)24.3611
2020's14 (3.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials9 (2.55%)5.53%
Reviews0 (0.00%)6.00%
Reviews22 (6.23%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1 (0.28%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other321 (90.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]